Mary Canning Ph.D.
Mary joined Epidarex as an Associate in 2013. She has more than 15 years of experience in the commercialization of early-stage health science technologies. Prior to joining Epidarex she led commercialisation of intellectual property from a number of leading UK medical research institutes with MRC Technology (now LifeArc). She previously oversaw the life science portfolio for the Scottish Enterprise Proof of Concept Programme, a non-dilutive fund for supporting spin-out opportunities from Scottish academic institutions.
Mary serves on the Board of Directors of Epidarex portfolio companies LUNAC Therapeutics, Caldan Therapeutics and Harness and a Board Observer with Dunad Therapeutics, Leucid Therapeutics and Curve Therapeutics. She is a also on the Board of Directors of the University of Glasgow’s investment subsidiary GU Holdings.
Mary has a Ph.D. in Molecular Biology from the University of Edinburgh and undertook postdoctoral research at the University of Glasgow